We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.78B
AUM Growth
-$1.32B
Cap. Flow
-$329M
Cap. Flow %
-4.22%
Top 10 Hldgs %
29.03%
Holding
186
New
13
Increased
33
Reduced
45
Closed
29

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$254M
2
PFE icon
Pfizer
PFE
+$130M
3
CMPX icon
Compass Therapeutics
CMPX
+$71.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$64.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$61.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$156M
2
ELV icon
Elevance Health
ELV
+$77.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M
4
PGNY icon
Progyny
PGNY
+$71.1M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$68.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.32%
2 Industrials 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$374M 4.8%
6,028,307
– –
BMY icon
2
Bristol-Myers Squibb
BMY
$130B
$271M 3.48%
4,339,800
-175,600
-4% -$10.3M
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$269M 3.46%
2,500,055
-110,300
-4% -$12M
BSX icon
4
Boston Scientific
BSX
$68.5B
$236M 3.03%
5,552,300
-281,300
-5% -$11.8M
THRX
5
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$214M 2.74%
+16,838,668
New +$254M
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.34B
$213M 2.74%
13,944,680
– –
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$209M 2.69%
1,426,400
+53,200
+4% +$8.26M
PMVP icon
8
PMV Pharmaceuticals
PMVP
$58.7M
$169M 2.18%
7,330,423
– –
PFE icon
9
Pfizer
PFE
$144B
$154M 1.99%
+2,615,400
New +$130M
HUM icon
10
Humana
HUM
$46.7B
$148M 1.9%
318,300
-16,700
-5% -$7.39M
ABBV icon
11
AbbVie
ABBV
$465B
$145M 1.86%
1,068,800
-351,800
-25% -$41.6M
VRTX icon
12
Vertex Pharmaceuticals
VRTX
$124B
$145M 1.86%
658,100
-219,300
-25% -$42.6M
EW icon
13
Edwards Lifesciences
EW
$48.2B
$139M 1.79%
1,076,200
-50,200
-4% -$5.86M
MRK icon
14
Merck
MRK
$326B
$136M 1.75%
1,779,300
-1,953,100
-52% -$156M
UNH icon
15
UnitedHealth
UNH
$389B
$136M 1.75%
271,000
-118,700
-30% -$53.7M
ISRG icon
16
Intuitive Surgical
ISRG
$130B
$134M 1.73%
373,800
-45,000
-11% -$15.5M
NTRA icon
17
Natera
NTRA
$36.1B
$132M 1.7%
1,413,985
-158,815
-10% -$16.5M
ACET icon
18
Adicet Bio
ACET
$76.7M
$130M 1.67%
465,446
+13,392
+3% +$2.3M
ARQT icon
19
Arcutis Biotherapeutics
ARQT
$3.55B
$126M 1.62%
6,073,850
– –
PRLD icon
20
Prelude Therapeutics
PRLD
$370M
$125M 1.61%
10,039,691
– –
SYK icon
21
Stryker
SYK
$133B
$124M 1.6%
465,300
+127,900
+38% +$33.6M
GH icon
22
Guardant Health
GH
$19B
$123M 1.58%
1,227,400
– –
IOVA icon
23
Iovance Biotherapeutics
IOVA
$2.1B
$121M 1.56%
6,337,700
-307,400
-5% -$6.77M
XBI icon
24
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$113M 1.45%
1,009,700
-56,000
-5% -$6.75M
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
$101M 1.3%
655,600
+387,600
+145% +$64.9M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2021 Portfolio in Review

As of Q4 2021, OrbiMed held 186 positions worth $7.78B, down 15% from $9.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

OrbiMed withdrew a net $329M in Q4 2021, closing 29 positions and reducing 45 holdings. Its most notable exit was Elevance Health, an estimated $77.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials and Technology.

Against the trend, OrbiMed opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $214M.

  • OrbiMed's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 16,838,668 shares worth $214M.
  • OrbiMed added most to Seagen Inc. Common Stock in Q4 2021, an estimated $64.9M increase.
  • OrbiMed's biggest Q4 2021 reduction was Merck, cutting an estimated $156M.
  • OrbiMed fully exited Elevance Health in Q4 2021, selling an estimated $77.2M.
  • OrbiMed's ten largest holdings make up 29% of its $7.78B portfolio in Q4 2021.
  • OrbiMed opened 13 new positions and closed 29 in Q4 2021.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $7.78B.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.